Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression

The company's founders are leading experts in the development of small molecule therapeutics for RNA-driven disease. Skyhawk's initial pipeline is focused on neurological and cancer indications WALTHAM, Mass., Jan. 23, 2018 -- (Healthcare Sales & Market... Biopharmaceuticals, Venture Capital, Personnel Skyhawk Therapeutics, RNA expression
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news